Trials / Completed
CompletedNCT00690378
Comparative Study of NXL104/Ceftazidime Versus Comparator in Adults With Complicated Urinary Tract Infections
Prospective, Multicenter, Investigator-blinded, Randomized, Comparative Study Estimate Safety, Tolerability, Efficacy of NXL104/Ceftazidime vs. Comparator Followed Appropriate Oral Therapy Treatment Complicated UTI Hosp Adults
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 137 (actual)
- Sponsor
- Pfizer · Industry
- Sex
- All
- Age
- 18 Years – 65 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to determine whether NXL104 plus ceftazidime is effective in the treatment of complicated urinary tract infections as compared to a comparator group.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | NXL104/ceftazidime | 125mg/500mg TID |
| DRUG | Imipenem/Cilastatin | 4 x daily |
Timeline
- Start date
- 2008-11-01
- Primary completion
- 2010-06-01
- Completion
- 2010-07-01
- First posted
- 2008-06-04
- Last updated
- 2018-05-25
- Results posted
- 2018-05-25
Locations
59 sites across 3 countries: United States, Jordan, Lebanon
Source: ClinicalTrials.gov record NCT00690378. Inclusion in this directory is not an endorsement.